LinXis Biopharmaceuticals (Netherlands)
A biopharmaceutical company pioneering Fibrobodies® and Fibrobody®-Drug Conjugates for targeted drug delivery to treat fibrotic diseases.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
LinXis Biopharmaceuticals is a company based in Amsterdam, Netherlands. It is the first to develop Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases. The company's mission is to have a turnkey solution for bringing drugs to targeted cells.
History
LinXis Biopharmaceuticals is a company in Amsterdam, Netherlands. It is the first to develop Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases. The company's mission is to have a turnkey solution for bringing drugs to targeted cells. In 2024, Guus van Dongen joined LinXis as Chief Scientific Officer. In 2025, LinXis received a TKI-PPP grant for the FibroTarget project, published a key paper on its lead Fibrobody® in EJNMMI, and joined the PHAEDRA-IMPACT consortium as an industrial partner.
Products and positioning
Fibrobodies®
Pan-fibrosis drug delivery vectors, small, smart, and selective, suitable for diagnosis and treatment, selective for activated myofibroblasts.
Fibrobody®-Drug Conjugates
How we deliver medicine to specific cells.
Fibrobody®-Tracer Conjugates
How we target specific cells.
Sources5 sources
- 1LinXis Biopharmaceuticalslinxispharmaceuticals.com
- 2Company | LinXis Biopharmaceuticalslinxispharmaceuticals.com
- 3Team | Company | LinXis Biopharmaceuticalslinxispharmaceuticals.com
- 4What’s new at LinXis | Company | LinXis Biopharmaceuticalslinxispharmaceuticals.com
- 5LinXis Biopharmaceuticals (Netherlands)wikidata.org
Cite this profile: Cite the canonical profile. /brand-wiki/linxis-biopharmaceuticals-netherlands · Editorial policy · How profiles are compiled